DS
SNOA icon

DRW Securities’s Sonoma Pharmaceuticals SNOA Stock Holding History

DRW Securities’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,015
Closed -$25.6K – 1433
2026
Q1 		$25.6K Sell
12,015
-48,962
-80% -$143K ﹤0.01% 1216
2025
Q4 		$222K Buy
60,977
+43,907
+257% +$162K 0.01% 891
2025
Q3 		$66.2K Buy
+17,070
New +$67.2K ﹤0.01% 1216

Other funds holding SNOA

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DRW Securities's SNOA Position: Q2 2026 in Review

DRW Securities sold out of Sonoma Pharmaceuticals (SNOA) in Q2 2026, closing a stake of 12,015 shares — an estimated $25.6K sold.

DRW Securities first reported a position in SNOA in Q3 2025 and held it in 3 quarters. The position peaked at $222K in Q4 2025. 14 funds tracked by Wall St. Rank hold SNOA as of Q2 2026.

  • DRW Securities reported no remaining Sonoma Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • DRW Securities sold 12,015 Sonoma Pharmaceuticals shares in Q2 2026, an estimated $25.6K.
  • DRW Securities first reported a position in Sonoma Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • DRW Securities's Sonoma Pharmaceuticals position peaked at $222K in Q4 2025.
  • 14 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.